Last Updated: 17 Oct 2024
Executive Summary
Orgenesis Inc. (ORGS) is a biotechnology company focused on cell and gene therapies. The company has a market capitalization of $16.17 million and trades on the NASDAQ exchange. Orgenesis reported a loss per share of $8.00 in the most recent quarter and has a trailing twelve-month revenue of $662,000. The company's financial performance has been weak in recent quarters, and its stock price has declined significantly from its 52-week high of $10.80.
Company Overview
Orgenesis was founded in 2007 and is headquartered in Germantown, Maryland. The company's mission is to develop and commercialize cell and gene therapies for the treatment of a variety of diseases. Orgenesis has a number of promising technologies in its pipeline, including its OPC-1 cell therapy for spinal cord injuries and its CAR-T cell therapy for cancer.
Fundamental Analysis
Orgenesis's financial performance has been weak in recent quarters. The company reported a loss per share of $8.00 in the most recent quarter, and its trailing twelve-month revenue was only $662,000. The company's gross margin was 54.4%, and its operating margin was -16.5%. Orgenesis has a number of challenges to overcome, including its lack of profitability, its dependence on a small number of products, and its competition from larger biotechnology companies.
Technical Analysis
Orgenesis's stock price has declined significantly from its 52-week high of $10.80. The stock is currently trading at $3.39, which is below its 50-day and 200-day moving averages. The stock's relative strength index (RSI) is 30.00, which indicates that it is oversold.
Short Term Outlook
Orgenesis's stock price is likely to remain under pressure in the short term. The company's financial performance has been weak, and its stock is trading below its moving averages. The stock's RSI is also indicating that it is oversold.
Long Term Outlook
Orgenesis has a number of promising technologies in its pipeline, and the company's long-term outlook is positive. However, the company's financial performance needs to improve in order for its stock price to recover.
Analyst Recommendations
Analysts are divided on Orgenesis's stock. One analyst has a buy rating on the stock, while another has a hold rating. The average analyst target price is $6.00.
